首页> 外国专利> Use of superoxide dismutase and reductase glutathione mimetics in the form of anticancer drugs

Use of superoxide dismutase and reductase glutathione mimetics in the form of anticancer drugs

机译:以抗癌药形式使用超氧化物歧化酶和还原酶谷胱甘肽模拟物

摘要

The use of a mimetic (I) of superoxide dismutase and glutathione reductase is claimed in the production of an anticancer medicament. An independent claim is included for a pharmaceutical composition containing (I) together with an antitumor agent (II) capable of inducing production of reactive oxygen oxygen species in cells. ACTIVITY : Cytostatic. In tests in mice with transplanted CT-26 tumors, intraperitoneal injection of mangafodipir (Ia) at 10 mg/kg 3 times per week reduced the tumor volume after 1 month by 54% compared with untreated controls; and if this treatment was commenced 2 hours after a single injection of oxaliplatin at 20 mg/kg the tumor volume after 1 month was by 63% compared with that in mice treated with oxaliplatin only. MECHANISM OF ACTION : Superoxide dismutase mimetic; glutathione reductase mimetic.
机译:在抗癌药物的生产中要求保护超氧化物歧化酶和谷胱甘肽还原酶的模拟物(I)的使用。独立的权利要求包括一种药物组合物,该药物组合物包含(I)和能够诱导细胞中反应性氧的产生的抗肿瘤剂(II)。活动:细胞静息。在对移植有CT-26肿瘤的小鼠进行的测试中,与未治疗的对照组相比,腹膜内注射mangafodipir(Ia)每周3次,每次10 mg / kg,1个月后肿瘤体积减少了54%。如果在单次注射20 mg / kg的奥沙利铂后2小时开始这种治疗,则与仅用奥沙利铂治疗的小鼠相比,在1个月后的肿瘤体积增加了63%。作用机理:超氧化物歧化酶模拟物;谷胱甘肽还原酶模拟物。

著录项

  • 公开/公告号DK1694338T3

    专利类型

  • 公开/公告日2009-02-16

    原文格式PDF

  • 申请/专利权人 UNIVERSITE PARIS DESCARTES;PROTEXEL;

    申请/专利号DK20040816432T

  • 申请日2004-12-17

  • 分类号A61K31/675;A61K31;A61K31/337;A61K31/513;A61K31/555;A61K31/661;A61K33/24;A61K45/06;A61P35;

  • 国家 DK

  • 入库时间 2022-08-21 19:28:09

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号